New developments in the treatment algorithm for peripheral neuropathic pain.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Pain medicine (Malden, Mass.)

• Publication date

  2011-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1526-4637.2011.01160.xPMID 21752181
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers.

  2010cited by this paper
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

  2010cited by this paper
• Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

  2010cited by this paper
• Long-term safety of NGX-4010, a high-concentration capsaicin patch, in patients with peripheral neuropathic pain.

  2010cited by this paper
• Assessment and treatment of psychosocial comorbidities in patients with neuropathic pain.

  2010cited by this paper
• The role of botulinum toxin in management of pain: an evidence-based review

  2010cited by this paper
• Spinal cord stimulation for failed back surgery syndrome: Outcomes in a workers’ compensation setting

  2010cited by this paper
• Spinal cord stimulation in a workers' compensation population: how difficult it can be to interpret a clinical trial.

  2010cited by this paper
• The burden of neuropathic pain: A systematic review and meta‐analysis of health utilities

  2010cited by this paper
• Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain

  2010cited by this paper
• Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study*

  2009cited by this paper
• Long‐term oral lacosamide in painful diabetic neuropathy: A two‐year open‐label extension trial

  2009cited by this paper
• Subcutaneous Botulinum toxin type A reduces capsaicin‐induced trigeminal pain and vasomotor reactions in human skin

  2009cited by this paper
• Anticonvulsants for Neuropathic Pain: Gaps in the Evidence

  2009cited by this paper
• A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster

  2009cited by this paper
• Efficacy and Safety of Lacosamide in Diabetic Neuropathic Pain: An 18-week Double-blind Placebo-controlled Trial of Fixed-dose Regimens

  2009cited by this paper
• Efficacy and Safety of 5% Lidocaine (Lignocaine) Medicated Plaster in Comparison with Pregabalin in Patients with Postherpetic Neuralgia and Diabetic Polyneuropathy

  2009cited by this paper
• Botulinum toxin for diabetic neuropathic pain

  2009cited by this paper
• NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain.

  2009cited by this paper
• Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study.

  2009cited by this paper
• Treatment of neuropathic pain: an overview of recent guidelines.

  2009cited by this paper
• Pathophysiology of fibromyalgia.

  2009cited by this paper
• Guidelines for the Diagnosis and Management of Neuropathic Pain: Consensus of a Group of Latin American Experts

  2009cited by this paper
• Neuropathic pain

  2008cited by this paper
• Role of pharmacogenetics in variable response to drugs: focus on opioids.

  2008cited by this paper
• Lacosamide

  2008cited by this paper
• NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study.

  2008cited by this paper
• Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain

  2008cited by this paper
• Role of pharmacogenetics in variable response to drugs: focus on opioids

  2008cited by this paper
• Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial.

  2008cited by this paper
• (–)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol Hydrochloride (Tapentadol HCl): a Novel μ-Opioid Receptor Agonist/Norepinephrine Reuptake Inhibitor with Broad-Spectrum Analgesic Properties

  2007cited by this paper
• EFNS guidelines on neurostimulation therapy for neuropathic pain

  2007cited by this paper
• Pharmacologic management of neuropathic pain: Evidence‐based recommendations

  2007cited by this paper
• Genetic factors in pain and its treatment

  2007cited by this paper
• Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society.

  2007cited by this paper
• Practice parameters for the use of spinal cord stimulation in the treatment of chronic neuropathic pain.

  2007cited by this paper
• EFNS guidelines on pharmacological treatment of neuropathic pain

  2006cited by this paper
• Tapentadol hydrochloride. Analgesic, Mu-opioid receptor agonist, noradrenaline reuptake inhibitor

  2006cited by this paper
• Duloxetine versus Routine Care in the Long-Term Management of Diabetic Peripheral Neuropathic Pain

  2006cited by this paper
• Algorithm for neuropathic pain treatment: An evidence based proposal

  2005cited by this paper
• Morphine, gabapentin, or their combination for neuropathic pain.

  2005cited by this paper
• Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.

  2002cited by this paper
• Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale

  2001cited by this paper

• Modeling an evaluation of the efficacy of the novel neuroanalgesic drug mirogabalin for diabetic peripheral neuropathic pain and postherpetic neuralgia therapy.

  2024cites this paper
• Development of Capsaicin-Containing Analgesic Silicone-Based Transdermal Patches

  2022cites this paper
• A review of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, for the treatment of peripheral neuropathic pain

  2021cites this paper
• A large-scale database study for the prescription status of a new voltage-gated Ca2+ channel α2δ ligand, mirogabalin, in Japan

  2021cites this paper
• The topical 5% lidocaine medicated plaster in localized neuropathic pain: a reappraisal of the clinical evidence

  2016cites this paper
• The 5% Lidocaine-Medicated Plaster: Its Inclusion in International Treatment Guidelines for Treating Localized Neuropathic Pain, and Clinical Evidence Supporting its Use

  2016cites this paper
• NEUROPATHIC PAIN SECTION Original Research Article Analgesic Efficacy and Safety of Medical Therapy Alone vs Combined Medical Therapy and Extraoral Glossopharyngeal Nerve Block in Glossopharyngeal Neuralgia

  2016cites this paper
• Recent Advances in the Pharmacological Management of Neuropathic Pain

  2016cites this paper
• Pharmacological Treatment of Painful Nerve Entrapment Syndrome

  2016cites this paper
• Multivariate proteomic analysis of the cerebrospinal fluid of patients with peripheral neuropathic pain and healthy controls – a hypothesis-generating pilot study

  2015cites this paper
• Neuropathic Orofacial Pain

  2015cites this paper
• The Cerebrospinal Fluid in Severe Pain Conditions : Clinical, Pharmacological and Proteomic Aspects

  2015cites this paper
• Place du patch de capsaïcine à haute concentration (8 %) dans la stratégie thérapeutique des douleurs neuropathiques périphériques

  2015cites this paper
• Clinical, Pharmacological and Proteomic Aspects

  2015cites this paper
• Chronic Abdominal Syndrome Due to Nervous Compression. Study of 100 Cases and Proposed Diagnostic-Therapeutic Algorithm

  2015cites this paper
• First-In-Human, Double-Blind, Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic Factor Family Member, in Subjects with Unilateral Sciatica

  2015cites this paper
• Analgesic topical capsaicinoid therapy increases somatostatin-like immunoreactivity in the human plasma.

  2014cites this paper
• Treatment of Acute and Chronic Pain in Horses

  2014cites this paper
• Acute Pain: Effective Management Requires Comprehensive Assessment

  2014cites this paper
• Peripheral Neural Sprouting Contributes to Endo-Induced Vaginal Hyperalgesia in a Rat Model of Endometriosis

  2014cites this paper
• Glossopharyngeal Neuralgia

  2013cites this paper
• [Medical treatment of neuropathic pain].

  2013cites this paper
• Spinal NTS2 receptor activation reverses signs of neuropathic pain

  2013cites this paper
• Comparison of the Effects of Pelargonic Acid Vanillylamide and Capsaicin on Human Vanilloid Receptors

  2013cites this paper
• Axonal voltage-gated ion channels as pharmacological targets for pain.

  2013cites this paper
• Sprouted Innervation into Uterine Transplants Contributes to the Development of Hyperalgesia in a Rat Model of Endometriosis

  2012cites this paper
• The challenge of understanding peripherally mediated antinociception

  2012cites this paper
• Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.

  2012cites this paper
• Effects of a Short Course of Oral Prednisolone in Patients with Bladder Pain Syndrome with Fluctuating, Worsening Pain despite Low-Dose Triple Therapy

  2012cites this paper
• Emerging concepts and treatment in neuropathic pain

  2012cites this paper
• Terapêutica Farmacológica da Dor Neuropática

  2012cites this paper
• Combination therapy with transdermal buprenorphine and pregabalin for chronic low back pain.

  2012cites this paper
• Accelerating the development of improved analgesic treatments: the ACTION public-private partnership.

  2011cites this paper